Neurocrine Biosciences, Inc. NBIX
NASDAQ · United States · Health Technology
$141.84+3.49 (+2.52%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in Philadelphia.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the Company's executive management team as Chief Medical Officer (CMO), effective immediately. By mutual agreement, Sanjay Keswani, M.D., will depart the Company.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.